


PHARMACEUTICAL 2017



Akebia Therapeutics Inc. Rank 157 of 313





PHARMACEUTICAL 2017



Akebia Therapeutics Inc. Rank 157 of 313

The relative strengths and weaknesses of Akebia Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Akebia Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 132% points. The greatest weakness of Akebia Therapeutics Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 74% points.

The company's Economic Capital Ratio, given in the ranking table, is -179%, being 238% points above the market average of -417%.

Input Variable	Value in 1000 USD
Assets, Current	296,321
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	114,268
Liabilities, Non-Current	27
Other Assets	1,283
Other Compr. Net Income	-42
Other Expenses	0
Other Liabilities	117,801
Other Net Income	2,248
Property and Equipment	2,612
Research and Development	115,785
Revenues	0
Selling, General and Administrative Expense	22,210

Output Variable	Value in 1000 USD
Assets	300,216
Liabilities	232,096
Expenses	137,995
Stockholders Equity	68,120
Net Income	-135,747
Comprehensive Net Income	-135,768
Economic Capital Ratio	-179%